ミトコンドリアDDSが拓く新しい薬剤学

  • 山田 勇磨
    北海道大学大学院薬学研究院薬剤分子設計学研究室

書誌事項

タイトル別名
  • Mitochondrial DDS Opens Innovative Pharmaceutics
  • Symposium Review ミトコンドリアDDSが拓く新しい薬剤学
  • Symposium Review ミトコンドリア DDS ガ ヒラク アタラシイ ヤクザイガク

この論文をさがす

抄録

  A variety of human diseases, including neurodegenerative disorders, ischemic heart disease, diabetes, and cancer have been reported to be associated with mitochondrial dysfunction. Because of this, mitochondrial therapy is expected to be useful and productive in the treatment of such diseases. We previously reported on the development of a MITO-Porter, a liposome-based nanocarrier that permits macromolecular cargos to be delivered into mitochondria via membrane fusion. Intracellular observations using the green fluorescence protein as a model macromolecule provided confirmation that a macromolecule could be delivered to mitochondria in living cells by the MITO-Porter. Here, we present our current findings on the development of mitochondrial medicine and mitochondrial gene therapy based on our mitochondrial drug delivery system (DDS). In this review, we propose “mitochondrial DDS” as a theme for “DDS research for innovative drug development” and discuss the contribution of mitochondrial DDS to innovative drug development.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 136 (1), 55-62, 2016-01-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (27)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報

問題の指摘

ページトップへ